Drug Profile
Mezagitamab - Takeda
Alternative Names: Anti-CD38 mAb; TAK-079Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Takeda
- Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic thrombocytopenic purpura; Multiple myeloma; Myasthenia gravis
- Phase I/II Systemic lupus erythematosus
- Phase I IgA nephropathy
- Discontinued Rheumatoid arthritis
Most Recent Events
- 14 Mar 2024 Mezagitamab - Takeda receives Fast Track designation for Idiopathic thrombocytopenic purpura [SC,Injection] in USA
- 14 Mar 2024 Mezagitamab - Takeda receives Orphan Drug status for Idiopathic thrombocytopenic purpura in USA
- 13 Mar 2024 Takeda plans to initiate a global Phase III trial of mezagitamab in idiopathic thrombocytopenic purpura in 2024